Study Overview
Sex: All
Age: 18 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers? yes
No Study Documents
Study Overview
Sex: All
Age: 18 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers? yes
No Study Documents
BGB-A317-302
Active, not recruiting
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
Beigene Study ID
BGB-A317-302
ClinicalTrials.gov ID
EudraCT Number
2017-003699-30
Clinical Drug Trials ID
CTR20171026
Sex: All
Age: 18 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers? yes
No Study Documents
Sex: All
Age: 18 Years and older (Adult, Older Adult)
Accepts Healthy Volunteers? yes
No Study Documents
BeiGene provides links to web sites of other organizations in order to provide visitors with certain information. A link does not constitute an endorsement of content, viewpoint, policies, products or services of that web site. Once you link to another web site not maintained byBeiGene Australia, you are subject to the terms and conditions of that web site, including but not limited to its privacy policy.
Click the link above to continue or CANCEL